Cytogenetics and molecular genetics of ovarian cancer

American Journal of Medical Genetics - Seminars in Medical Genetics

Volumn 115, Issue 3, 2002, Pages 157-163

  Wang, Nancy ^a,b  

^a Box 608 ^*  (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Chromosome microdissection; Chromosome transfer; Comparative genomic hybridization; Fluorescence in situ hybridization; Genetic changes; Microarray gene expression analysis; Ovarian cancer

Indexed keywords

ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME BAND; CHROMOSOME MICRODISSECTION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HEREDITY; HETEROZYGOSITY LOSS; HUMAN; INTERMETHOD COMPARISON; MOLECULAR GENETICS; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; CHROMOSOME 20; CHROMOSOME 6; CHROMOSOME BANDING PATTERN; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETICS; OVARY TUMOR; REVIEW;

CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS;

EID: 1842835868     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.10695     Document Type: Article

References (76)

1. Abeysinghe HR, Cedrone, E, Tyan T, Xu J, Wang N. 1999. Amplification of C-myc as the origin of the homogeneous staining region in ovarian carcinoma detected by micro-FISH. Cancer Genet Cytogenet 114:136-143.
2. Acquati F, Morelli C, Cinquetti R, Bianchi MG, Porrini D, Varesco L, Gismondi V. Rocchetti R, Talevi S, Possati L, Magnanini C, Tibiletti MG, Bernasconi B, Daidone MG, Shridhar V. Smith DI, Negrini M, Barbanti-Brodano G, Taramelli R. 2001. Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene 20(8):980-988.
3. Alvarez AA, Lambers AK, Lanaster JM, Maxwell GL, Ali S, Gumbs C, Berchuck A, Futreal PA. 2001. Allele loss on chromosome 1p36 in epithelial ovarian cancers. Gynecol Oncol 82(1):94-98.
4. Anzick SL, Kononen J, Walke RL, Axorsa DO. Tanner MM, Guan X-Y, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. 1997. AIB1, a steroid receptor co-activator amplified in breast and ovarian cancer. Science 277:965-967.
5. Arnold N, Hagele L, Walz L, Schempp W, Pfisterer J, Bauknecht T, Kiechle M. 1996. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. Genes Chromosom Cancer 16:46-54.
6. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. 1990. c-myc amplification in ovarian cancer. Gynecol Oncol 38:340-342.
7. Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfeiderer A, Wagner E. 1993. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothioneine in human ovarian carcinomas: Classification in malignant phenotypes. Cancer 71:419-429.
8. Bello MJ, Rey JA. 1990. Chromosome aberrations in metastatic ovarian cancer: Relationship with abnormalities in primary tumors. Int J Cancer 45(1):50-54.
9. Cao Q, Abeysinghe H, Chow O, Xu J, Kaung H, Fong C, Keng P, Insel RA, Lee WM, Barrett JC, Wang N. 2001. Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet 9:131-137.
10. Deger R.B, Faruqi SA, Noumoff JS. 1997. Karyotypic analysis of 32 malignant epithelial ovarian tumors. Cancer Genet Cytogenet 96:166-173.
11. Diebold J, Mosinger K, Peiro G, Pannekamp U, Kaltz C, Baretton GB, Meier W, Lohrs U. 2000. 20q13 and cyclin D1 in ovarian carcinomas: Analysis by fluorescence in situ hybridization. J Pathol 190:564-571.
12. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent J. 1999. Expression profiling using cDNA microarrays. Natire Genet 21: (Suppl 1):10-14.
13. Engelman JA, Zhang XL, Lisanti M. 1998. Genes encoding human caveolin-1 and-2 are colocalized to the D7S522 locus (&q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436:403-410.
14. Faulkner SW, Friedlander ML. 2000. Molecular genetic analysis of malignant ovarian germ cell tumors. Gynecol Oncol 77:283-288.
15. Fukushi Y, Sato S, Yokoyama Y. Kudo K, Maruyama H, Saito Y. 2001. Detection of numerical aberrations in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH. Eur J Gynaecol Oncol 22:23-25.
16. Gajewski W, Legare RD. 1998. Ovarian cancer. Surg Oncol Clin North Am 7:317-333.
17. Gallion HH, Powell DE, Smith LW, Morrow JK, Martin AW, van Nagell JR, Donaldson ES. 1990. Chromosome abnormalities in human epithelial ovarian malignancies. Gynecol Oncol 38:473-477.
18. Goldgar DE, Easton DE Cannon-Albright LA, Skolnick MH. 1994. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600-1608.
19. Guan X-Y, Cargile CB, Anzick SL, Thompson FH, Meltzer PS, Bittner ML, Taetle R. McGill JP, Trent JM. 1995. Chromosome microdissection identifies cryptic sites of DNA sequence amplification in human ovarian carcinoma. Cancer Res 55:3380-3385.
20. Guan X-Y, Sham JST, Tang TC-M. Fang Y, Huo K-K, Yang J-M. 2001. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 61(9):3806-3809.
21. Hauptmann S, Dietel M. 2001. Serous tumors of low malignant potential of the ovary: Molecular pathology. Part 2. Virchows Arch 438(6):539-551.
22. Heid CA, Stevens JLK, Williams PM. 1996. Real time quantitative PCR. Genome Res 6:986-994.
23. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. 2001. Coordinately up-regulated genes in ovarian cancer. Cancer Res 61:3869-3876.
24. Imoto I, Pimkhaokham A, Watanabe T, Saito-Ohara F, Soeda E, Inazawa J. 2000. Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE-superclass, in ovarian cancer cell lines. Biochem Biophy Res Commun 276:264-270.
25. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BYU, Gasson JC, Chang DD. 2000. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 60:6744-6749.
26. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW. 1995. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55:6172-6180.
27. Jacobsen A, Arnold N, Weimer J, Kiechle M. 2000. Comparison of comparative genomic hybridization and interphase fluorescence in situ hybridization in ovarian carcinomas: Possibilities and limitations of both techniques. Cancer Genet Cytogenet 122:7-12.
28. Jenkins RB, Bartelt D Jr, Stalboerger P, Persons D, Dahl RJ. Podratz K, Keeney G, Hartmann L. 1993. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-86.
29. Kallionemi A, Kallionemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkle D. 1992. Compararive genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821.
30. Kallionemi OP, Kallionemi A, Piper J, Isola J, Waldmann FM, Gray JW, Pinkle D. 1994. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer 10:231-243.
31. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. 2001. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91:534-540.
32. Kiechle-Schwarz M, Bauknecht T, Karck U, Kommoss F du Bois A, Pfleiderer A. 1994. Recurrent cytogenetic aberrations and loss of constitutional heterozygosity in ovarian carcinomas. Gynecol Oncol 55:198-205.
33. Kovaks G. 1979. Homogeneously staining regions on marker chromosomes in malignancy. Int J Cancer 23:299-301.
34. Kruzelock R.P. Cuevas BD, Wiener JR, Xu FJ, Yu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC Jr. 2000. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19:6277-6285.
35. Kurose K, Zhou X-P, Araki T. Cannistra SA. Maher ER, Eng C. 2001. Frequent loss of PTEN expression is linked to elevated phosphorylated akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158:2097-2106.
36. Lassus H, Laitinen MP, Anttonen M, Heikinheimo M, Aaltonen LA, Ritvos O, Butzow R. 2001. Comparison of serous and mucinous ovarian carcinomas: Distinct pattern of allelic loss at distal 8p and expression of transcription factor CATA-4. Lab Invest 81:517-526.
37. Launonen V, Stenback F, Puistola U, Bloigu R, Huusko P, Kytola S, Kauppila A, Winqvist R. 1998. Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions. Gynecol Oncol 71:299-304.
38. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R. 2000. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: Correlation to clinicopathological variables. Cancer Genet Cytogenet 122:49-54.
39. Leng J, Lang J, Shen K, Guo L. 1997. Over-expression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J 12:67-70.
40. Levan A. Levan G, Mitelman F. 1977. Chromosomes and cancer. Hereditas 86:15-30.
41. Nacheva EP, Grace CD, Bittner M, Ledbetter DH, Jenkins RB, Green AR. 1998. Comparative genomic hybridization: A comparison with molecular and cytogenetic analysis. Cancer Genet Cytogenet 100:93-105.
42. Narod SA, Madlensky L, Bradley L, Cole D, Tonin P, Rosen B, Risch HA. 1994. Hereditary and familiar ovarian cancer in Souther Ontario. Cancer 74:2341-2346.
43. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP. 2001. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7:2380-2386.
44. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai K, Takagi T, Nakamura Y. 2000. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60:5007-5011.
45. Patael-Karasik Y, Daniely M, Gotlieb WH. Ben-Baruch G, Schiby J, Barakai G, Goldman B, Aviram A, Friedman E. 2000. Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. Cancer Genet Cytogenet 121:26-32.
46. Pejovic T. 1995. Genetic changes in ovarian cancer. Ann Med 27:73-78.
47. Pejovic T, Helm S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM, Furgyik S. Helm G, Himmelmann A, Willen H, Mitelman F. 1992. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosom Cancer 4:58-68.
48. Pribill I, Speiser P, Leary J, Leodolter S, Hacker NF, Friedlander ML, Birnbaum D, Zeillinger K, Krainer M. 2001. High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genet Cytogenet 129:23-29.
49. Rimessi P, Gualandi F, Morelli C, Trabanelli C, Wu Q, Possati L, Montesi M, Barrett JC, Barbanti-Brodano G. 1994. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene 9:3467-3474.
50. Roberts CG, Tattersall MH. 1990. Cytogenetic study of solid ovarian tumors. Cancer Genet Cytogenet 48:243-253.
51. Sandhu AK, Kaur GP, Reedy ED, Rane NS, Athwal RS. 1996. A gene on 6q14-21 restores senescence to immortal ovarian tumor cells. Oncogene 12:247-252.
52. Sasno H. Garett CT, Wilkinson DS, Silverberg S, Comerford J, Hyde J. 1990. Protooncogene amplification and tumor ploidy in human ovarian neoplasms. Hum Pathol 21:382-391.
53. Schena M, Shalon D, Davis KW, Brown PO. 1995. Quantitative monitoring of gene expression patterns with a complimentary DNA microarray. Science 270:467-470.
54. Schreiber G, Dubeau L. 1990. c-myc protooncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. Am J Pathol 137:653-658.
55. Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Tanaka K, and the Japanese Familial Ovarian Cancer Study Group. 2001. Localization of a novel susceptibility gene for familiar ovarian cancer to chromosome 3p22-p25. Hum Mol Genet 10:1421-1429.
56. Simon R, Desper K, Papadimitriou CH, Peng A, Alberts DS, Taetle R, Trent JM, Schaffer AA. 2000. Chromosome abnormalities in ovarian adenocarcinoma. III. Using breakpoint data to infer and test mathematical models for ongocenesis. Genes Chromosom Cancer 28:106-120.
57. Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Takushiji M, Testa JR. 1997. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosom Cancer 20:320-328.
58. Suzuki S, Moore DH Jr, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. 2000. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385.
59. Taetle R, Aickin M, Panda L, Emerson J, Roe D, Thompson E Davis J, Trent J, Alberts D. 1999a. Chromosome abnormalities in ovarian adenocarcinoma. II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosom Cancer 25:46-52.
60. Taetle IL, Aickin M, Yang JM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, Davis JR, Trent J, Alberts DS. 1999b. Chromosome abnormalities in ovarian adenocarcinoma. I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosom Cancer 25:290-300.
61. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P. Pejovic T, Borg A, Isola JJ. 2000. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6:1833-1839.
62. Tapper J, Sarantaus L, Vahteristo P, Nevanlinna H, Hemmer S, Seppala M, Knuutila S, Butgors R. 1998. Genetic changes in inherited and sporadic ovarian carcinoma by comparative genomic hybridization: Extensive similarity except for a difference at chromosome 2q24-q32. Cancer Res 58:2715-2719.
63. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. 2001. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 128:1-6.
64. Thompson FH, Emerson J, Alberts D, Liu Y, Guan X-Y, Burgess A, Fox S, Taetle R, Weinstein R, Makar R, Powell D, Trent J. 1994. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 73:33-45.
65. Tibiletti MG, Trubia M, Ponti E, Sessa L, Acquati F, Furlan D, Bernasconi B, Fichera M, Mihalich A, Ziegler A, Volz A, Facco C, Riva C, Cremonesi L, Ferrari M, Teramelli R. 1998. Physical map of the D6S149-D6S939 region on chromosome 6q27 and its involvement in benign surface epithelial ovarian tumors. Oncogene 16:1639-1642.
66. Tibiletti MG, Bernasconi B. Furlan D, Bressan P, Cerutti R, Facco C, Franchi M, Riva C, Cinquetti R, Capella C, Taramelli R. 2001. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms. Clin Cancer Res 7:3404-3409.
67. Trent JM, Standridge EJ, McBride HL, Meese EU, Casey G, Araujo DE, Witowski CM, Nagle RB. 1990. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247:568-571.
68. Wan M, Sun T, Vyas R, Zheng J, Granada E, Dubeau L. 1999. Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25. Oncogene 18:1545-1551.
69. Wang VW, Bell DA, Berkowitz RS, Mok SC. 2001. Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors. Cancer Res 61:4169-4174.
70. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, Sato A, Inazawa J. 2001. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81:172-177.
71. Watson RH, Neville PJ, Roy WJ Jr, Hitchcock A, Campbell IG. 1998. Loss of heterozygosity on chromosome 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 17:207-212.
72. Weitzel JN, Patel J, Smith DM, Goodman A, Safaii H, Ball HG. 1994. Molecular genetic changes associated with ovarian cancer. Gynecol Oncol 55:245-252.
73. Welcsh PL, King MC. 2001. BRCA1 and BKCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713
74. Wong KK, Cheng RS, Mok SC. 2001. Identification of differentially expressed genes from ovarian cancer cells by MICKOMAX cDNA microarray system. Biotechniques 30:670-675.
75. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Duo W, Gray JW, Sciliano M, Mills GB, Bast RC Jr. 1999. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96:214-219.
76. Zweemer RP, Ryan A, Snijders AM, Hermsen MA, Meijer GA, Beller U, Mendo FH, Jacobs IJ, Baak JP, Verheijen RH, Kenemans P, van Diest PJ. 2001. Comparative genomic hybridization of microdissected familial ovarian carcinoma: Two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 81:1363-1370.